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BACKGROUND 
Celiac Disease 
Celiac Disease (CD) is a gluten-sensitive enteropathy which occurs in 
1% of Caucasian populations. This multifactorial disorder arises, in 
genetically susceptible individuals, following exposure to dietary wheat 
gluten, and similar proteins (prolamins), present in rye and barley. 
Susceptibility to develop celiac disease is strongly influenced by 
inherited factors, as confirmed by high prevalence (~10%) among first-
degree relatives of CD patients (1). 
Main genetic factors involved in celiac disease are the Human Leukocyte 
Antigen (HLA) Class II genes that encoded HLA-DQ2 (2) and HLA-
DQ8 heterodimers (3). The strong genetic influence related to celiac 
disease is also supported by a high concordance rate (75%) in 
monozygotic twins, while the concordance rate between dizygotic twins 
is at the 11%. (4,5). Despite the frequency of celiac HLA class II in 
general population is ~30%, only 1% develops celiac disease (6). These 
features suggest that these particular HLA molecules are necessary but 
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not sufficient for development of celiac disease, and other genetic or 
environmental factors probably are involved in disease (7). 
 
Clinical aspects and therapy 
In susceptible individuals, the ingestion of gluten activates an immune 
cascade responsible for lymphocytic infiltration of proximal part of the 
small bowel (8), and for destruction of the intestinal mucosa epithelium 
(9).  
The intestinal damage can range from very mild degree, identified in 
atypical or silent celiacs, with little or absent histological intestinal 
lesions, until high or total degree of villous atrophy. In this context an 
important support to clinical practice and diagnosis was given by Marsh 
studies. Marsh classification categorized small intestinal damage from 
normal to complete atrophy, and made possible the interpretation of 
gluten induced damage (10). 
From the clinical point of view, celiac disease presents with different 
forms (11). In the classical or typical form, the ingestion of gluten 
5 
 
induced an enteropathy presenting with signs of malabsorption (such as 
diarrhoea or malnutrition) or malabsorption syndrome (weight loss, 
steatorrhoea and oedema secondary to hypoalbuminemia). From 
histological point of view, the disease is characterized by villous atrophy 
and crypt hyperplasia occurring after introduction of gluten.  
In addition to the classical form, most common in childhood, the 
pathology may occur as "atypical". These patients have not weight loss, 
but present any of the following symptoms such as gastrointestinal 
symptoms, including symptoms suggestive of irritable bowel syndrome 
and liver dysfunction; extraintestinal manifestations, such as metabolic 
disease/symptoms (failure to thrive, thyroid dysfunction); neurologic 
findings, including depression and gluten ataxia; reproductive disease, 
including abnormalities in menarche and menopause; oral/cutaneous 
disease, including dermatitis herpetiformis and skeletal findings (12, 13).  
Sometimes, the disease may be "silent", with no symptoms, but in the 
presence of small intestine atrophy. In most cases of this category have 
been identified by screening programs involving, apparently, healthy 
subjects o first degree relatives of patients.  
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In addition, there are genetically predisposed children, who have anti-
tissue transglutaminase auto-antibodies (tTG2), the serological marker of 
the disease, but a normal, not damaged, small bowel mucosa (13). Some 
of these individuals, called “potential celiac”, will develop the disease 
over the time (14, 15). 
Gluten-free diet is, currently, the only valid treatment of celiac disease 
(16). The gluten-free diet consist in an alimentary regimen avoiding 
wheat, rye, barley, and all related cereals including spelt (a wheat 
variant). Among cereals Oats seems to be no toxic in a great part of 
celiac, despite that, it is not recommended, since not tolerated by 
subgroup of patients. For this reason its use is under debate (16, 17).  
So far it‟s not identified any safe threshold for gluten intake in celiac. 
(16). The guidelines of Codex Alimentarius limits the amount of gluten 
in products for the diets of celiac subjects at less than 20 ppm (12). 
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Alternative therapies  
The gluten free diet allows the restoration of normal intestinal 
morphology and function, but does not guarantee the recovery of 
tolerance to these grains, even after many years. Furthermore, gluten free 
diet is more expensive, and for some patients it has a reduced 
palatability, responsible of poor compliance.  
For all these reasons, recently great research efforts were made to 
identify a pharmacological therapy alternative to the gluten-free diet 
(GFD), aimed to recover the immune tolerance to ingested gluten, and to 
improve the patients‟ quality life (18).  
The identification of a new alternative therapy could be important for a 
part of treated celiac patients to whom the GFD fails. In these patients 
the symptoms remained, or reappear, even having gluten free diet. This 
may be related to inadequate adherence to the diet, or to unintentional 
ingestion of gluten caused by contamination. A part of these patients are 
represented by refractory celiac in which the exclusion of gluten from 
dietary is inefficacious (refractory CD), and serious complications can 
occur (19, 20). 
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Several of these studies are address to search ancient wheats devoid of 
immunogenic sequences, or other naturally non toxic cereals.  
However a great part of them were addressed to identify new strategies 
to detoxify gluten. It has been widely shown that gliadin peptides are 
characterized by high content in proline that makes it highly resistant to 
gastrointestinal digestion (21).  
For this reason same research efforts were oriented to digest gluten 
fragments by oral supplementation of proteolytic enzyme (21, 22) in 
order to promote complete digestion of cereal proteins, and thus destroy 
immune-stimulatory T-cell epitopes. One drug based on this approach, 
currently under clinical trial is the enzyme formulation ALV003. This 
drug seems to be well tolerated by celiac patients, and adverse reactions 
were not identified. However it‟s not possible to be sure about long term 
effects yet (23). Furthermore currently under clinical trials is AN-PEP a 
prolyl oligopeptidases derived from Aspergillus niger. This enzyme is 
able to cleave gluten. Currently AN-PEP appears to be tolerated, in 
celiac patients, but a further investigation is required (24, 25).
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Another approach is based on proteolytic digestion, and focused on pre-
treatment of wheat with lactobacilli able to proteolyze proline-rich gluten 
peptides (26). In vitro studies confirmed the degradation of toxic 
epitopes (27). 
Another strategy addressed to transamidation of wheat flour it has been 
implemented. Using this approach the stimulatory activity of gliadin is 
abolished, while an appropriate amine group donor blocked gliadin 
immunotoxicity preserving the integrity of the structure (28). 
Furthermore studies are instead addressed to reduce intestinal 
permeability that is a typical feature of celiac disease. It has been 
demonstrated that this alteration is due to up-regulation of zonulin that 
causes an opening of tight junctions and a rapid increase in intestinal 
permeability (29). The use of an inhibitor of zonulin such may have an 
important effect on gliadin access to GALT. AT-1001 peptide has been 
synthesized to prevent the up-regulation of zonulin (30). 
Despite all these approaches, the peptide-based immunotherapy 
represents one of the most interesting hopes for the future. This kind of 
immunotherapy, already used in some allergies, aims to induce 
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tolerization of reactive T cells and consequently control of inflammation 
(31). Recently it has been given a great attention to identification of 
gliadin peptides. Anderson and co-workers, in fact in 2000 used a new in 
vivo system to identify gluten specific T cells, that overcomes the 
problems related with the used of intestinal T cells. In particular this 
technique is based on administration of wheat bread for few days (3 
days) to celiac patients on GFD, followed by the use of IFN- EliSpot 
Assay for detection of intestinal gluten specific CD4
+
T lymphocytes in 
peripheral blood. In fact specific gluten T cell lines can be isolated from 
intestinal biopsies cultured in vitro, furthermore these specific T cells, 
can be found in peripheral blood 3 or 6 days following oral challenge 
with gluten, in celiac patients on gluten free diet (GFD) (32). 
Using this approach, J.A. Tye-Din and co-workers, following a challenge 
with different cereals, screened a large library of 20-mer epitopes 
derived from different prolamines. Thanks to this new approach it was 
provided a comprehensive understanding of the T cell 
immunostimulatory gluten peptides in HLA-DQ2.5 adults with CD (33). 
Using both approaches, different studies have identified peptides with 
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common immunogenic sequence. This peculiarity emphasized a 
convergence between in vitro and in vivo findings.  
 
Gluten: main trigger of the disease  
As mentioned above, gluten is the main environmental factor involved in 
celiac disease, and it is the main storage protein of seed in many cereals, 
including wheat, barley, and rye. Gluten is composed by hundreds of 
proteins presents as mono-oligomeric o polymers linked by disulphide 
bonds. 
Gluten is characterized by high content of proline, which makes it 
resistant to gastrointestinal enzyme degradation. Due to this chemical 
feature following ingestion of gluten, gut lumen, and, in particular the 
intestinal mucosa come in contact with long fragments (10-50 residues) 
of gluten, that are crucial for inflammatory activations. Furthermore 
these long fragments are substrate for the enzyme tissue 
transglutaminase (tTG2), which converts glutamine residues into 
glutamate. This process, known as deamidation, increases the gluten 
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negative residues, and, increases the ability of gluten to bind HLA DQ2 
or DQ8, when they are presented by antigen-presenting cells (APC) (34). 
Gluten is composed by a mixture of water insoluble proteins gliadins and 
glutenins. Gliadins are monomeric alcohol insoluble proteins (27-70 
KDa), and are rich in prolamine. Gliadins are divided, according their 
electrophoresis mobility, into three families: -- and - gliadins that 
even so have similar primary structure. Glutenins are divided into low 
molecular (LMW 30-60 kDa) and high molecular weight (HMW, 80-120 
kDa) (35). The great heterogeneity found in gliadin and glutenin is 
responsible of presence of many distinct T cell epitopes (34). 
 
Genetics of Celiac Disease: HLA and non HLA genes  
From the pathogenic point of view, celiac disease is a multifactorial 
disease, determined by the interaction of genetic and environmental 
factors. In fact, it only develops in genetically susceptible individuals, 
which express HLA class II molecules DQ2 and/or DQ8. Over 90% of 
patients with celiac disease express HLA DQ2 heterodimer encoded by 
allele HLA-DQA1*05 and by allele HLA-DQB1*02 (36), while the 
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remaining express the heterodimer DQ8, encoded by allele DQA1*03 
and by allele DQB1*0302 (37). 
The fact that HLA DQ2/DQ8 alleles are very common in the healthy 
population suggests that these molecules are necessary but not sufficient 
for the development of the disease. In fact, the frequency of HLA class II 
molecules associated to risk of celiac disease is approximately 30% in 
Caucasians, but only 1-2% of population will develop the disease (38). It 
is widely demonstrated that HLA class II molecules account for about 
35% of the genetic risk, and, at the present there are numerous other non-
HLA genes candidate as factors predisposing to the development of 
celiac disease (39).  
In the identification of non HLA genes, the role of genome wide 
association studies (GWAS) is crucial. The genome wide association 
studies, using SNP (tag single nucleotide polymorphism) technique, 
identified a large number of genes implicated in celiac disease, and in 
other auto-immune disease. In particular, on 40 genomic regions, 64 
genes have been identified as candidate genes. These regions explain 
only 5% of the genetic inheritance (39). Almost all genes found 
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associated with celiac disease are involved in the immunological 
cascade, in particular those coding for chemokine receptor activity, T 
cell activation etc. One important region identified corresponds to the 
locus present on chromosome 4q27, in which were identified genes 
encoding interleukin-2 (IL-2), and IL-21, as well as other genes (40). 
Both these cytokines are important for proliferation and maturation of T-
lymphocyte. In another locus identified on chromosome 3q25, were 
identified genes encoding IL-12, while genes found on chromosome 
2q12, expressed IL18-receptor. Both these two cytokines are involved in 
the regulation of IFN- production (40, 41). 
All these findings confirmed that CD is a T cell-mediated immune 
disorder (34). 
 
Immunopathogenesis of CD 
As mentioned above, the main environmental factor that triggers celiac 
disease is gluten. In the celiac gut, the partially digested gluten (that is 
highly resistant to intestinal degradation) passes through the epithelial 
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barrier via epithelial transcytosis, or by an increased epithelial tight 
junctional permeability, that represents a disease hallmark (42). 
In the lamina propria gluten peptides are processed by APC, and 
presented by the surface HLA class II DQ2 or DQ8 molecules, after a 
specific reaction of deamidation by tTG2.  
tTG2 is an ubiquitously enzyme expressed by almost all cells types. It is, 
usually, presents in enzymatically inactive form in the intracellular 
compartment, where binds GTP molecules. In particular situation, as for 
example under mechanical or inflammatory stress, and in reducing 
environment, tTG2 is released in the extracellular matrix, where in 
presence of low levels of GTP, and high levels of Ca2
+
, acquires an open 
enzymatically active form (43). 
tTG2 catalyzes different cross-linking reaction. In particular, catalyzes a 
covalent process of transamidation, that is an irreversible cross-linking 
of a protein, such as gluten, with a glutamine residue (glutamine donor), 
to a second protein with a lysine residue (glutamine acceptor). This 
process generates an irreversible isopeptidyl bond. Alternatively, in 
absence of lysine residue, and at relatively low pH (<7), TG2 converts 
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glutamine (neutral) in glutamic acid (negatively) residue. TG2 activity is 
highly site-specific because deamidate only glutamine residue present in 
QXP site (Q is a glutamine, P is a prolin and X is any amminoacid). This 
process of deamidation create negatively charged residue glutamic acid, 
that facilitates the binding of gluten to HLA-DQ2 and HLA-DQ8, 
present on APCs, who bind preferentially peptides that contain amino 
acid with negative charge (44,45).  
Following deamidation, gluten peptides acquire negative charged, and 
bind strongly to the specific HLA molecules (46). The subsequent 
adaptive response is mediated by CD4
+
T cells that recognise the HLA 
gluten complex, and produced pro-inflammatory cytokines mainly IFN-
responsible for the intestinal damage. This cytokine is one of the main 
mediators of the pro-inflammatory cascade, and its production is 
associated with the activation of matrix metalloproteinase (MMPs), by 
myofibroblasts, which contributes to the mucosal remodelling and 
villous atrophy, typical of celiac disease (47). 
Recently it has been identified one of the main immunogenic peptide of 
gliadin. This fragment of 33 aminoacids (33-mer), mapping N-teminal 
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region (57-68) of α-gliadin, is resistant to gastrointestinal degradation 
and is able to stimulate a strong immune response CD4
+
 cells mediated 
in DQ2
+
 celiacs (48). 
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CHAPTER I 
Identification of gliadin peptides restricted by the HLA Class I 
heterodimers encoded by A*0101 and B*0801 alleles, in strong 
linkage with the celiac disease-associated DR3-DQ2 haplotype 
1.1 INTRODUCTION  
1.1.1 Role of HLA Class-I restricted, adaptive CD8
+
 T cells  
Even though it has been demonstrated that CD is mediated by HLA class 
II genes, and that CD4
+
T cells are responsible of intestinal damage, one 
of the most characteristic features of CD intestinal biopsies is a massive 
infiltration of the epithelium and lamina propria by CD8
+
T lymphocytes. 
This CD8
+
T cell infiltration is present in all form of celiac disease 
intestinal lesions, but very little is known about its function in celiac 
disease pathogenesis (1).  
CD8
+
T cells are responsible for the destruction of cells infected by 
viruses and other intracellular pathogens, and stimulate the immune-
responses when immunogenic epitopes were presented on surface of 
Human Leukocyte Antigens (HLA) class I by Antigen Presenting Cells 
(APC). 
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HLA class I molecules are composed by two chains linked by non 
covalent bond: alpha and 2-microglobulin. The alpha chain is highly 
polimorfic, while β2-microglobulin results monomorfic. The alpha chain 
is formed by three extracellular domains, α1 (N-ter), α2, and α3 of about 
90aa, by one transmembrane domain, and by one cytoplasmic domain. 
First two domains create a binding pocket able to interact with epitopes 
presented by APC. The third domain, fold in Ig-like (Immunoglobulin-
like) domain. β2-microglobulin, is composed by 100 aa, and plays an 
important structural role. The antigens were recognized and processed by 
APC, to be presented to T lymphocyte (2). 
HLA class I are highly polimorfic, and this feature lead these molecules 
to recognize a high number of peptides. CD8
+
T lymphocyte recognize 
peptides of 8-12 aa in length, when they are presented by HLA class I 
molecules (3). Following presentation cytotoxic T lymphocyte release 
INF-γ, and stimulate the lysis of target cells. These cells in fact own 
granules permeate with serine protease as well as granzyme-β (GrB), 
perforin and proteoglycan. CD8
+
T lymphocyte interact with target cells 
and release for exocytosis the granzyme-β, and other enzyme responsible 
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of their lysis. Following CD8
+
 cells, detached from these target cells, are 
able to recognize other HLA-peptides complex (4). 
Several studies have suggested a potential role for class I-restricted T 
cells in autoimmune disease, as insulin dependent diabetes mellitus, or 
multiple sclerosis, but in celiac disease has not been demonstrated a clear 
genetic association with any HLA classes I genes.  
Gianfrani and co-workers have reported a possible involvement of HLA 
class I genes in celiac disease, and examined the link between celiac 
disease and CD8
+
T cell response. In particular, the Authors analyzed the 
immune responses to a panel of gliadin peptides high binders to HLA-A2 
molecule, in A2 positive celiac patients. Thanks to this work has been 
described a 10-mer A gliadin peptides (pA2 123-132) that stimulate HLA 
A2 restricted CD8
+ 
T lymphocyte from peripheral blood and intestinal 
mucosa of celiac patients (5).  
By a further ex vivo study, it has been demonstrated that this peptide 
stimulates an immune response both in the lamina propria and in the 
epithelium in organ culture system. The cytotoxic CD8
+
T cells activated 
in celiac mucosa of A2 celiac, react to epithelial CaCo2 (HLA A2
+
), 
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previously pulsed with pA2 peptide, and stimulate the production of IFN-
, and the release of Granzyme-B, and lead to the apoptosis of these 
target cells (6).  
These evidences suggest that HLA class I could be play a role in the 
immunopathogenesis of disease.  
Overall these data demonstrated that CD8
+
T cells, which massively 
infiltrate the celiac disease intestinal mucosa, may also, in addition to a 
role in innate immunity (T cell receptor independent), already 
demonstrated perform specific types of response against gluten, 
following presentation of peptides by HLA class I, and participate to 
adaptive immunity.  
To reinforce the hypothesis suggesting the possible involvement of 
adaptive CT8
+
T cells in celiac disease, recently Davis and co-workers 
observed in peripheral blood of DQ2
+
 celiac, following gluten challenge, 
along with the increase of gluten specific CD4
+
T lymphocytes, a 
remarkable increased of -and - CD8+T lymphocytes. These 
lymphocytes, expressed both gut homing markers such as CD103 
(intestinal epithelial-homing markers E), and 7 integrins, and also the 
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activation marker CD30. In addition the Authors analyzed the T cell 
receptor (TCR) of T cell activated, and results suggest that CD8
+
T cells 
are activated in antigen specific manner, in response to dietary gluten. 
Gluten oral administration induced a mobilization of CD8
+
T 
lymphocytes from small intestinal mucosa to peripheral blood (7). 
 
1.1.2 Role of HLA class I A*01 and B*08 in celiac disease 
Celiac disease, as well as other autoimmune diseases, is due to genetic 
and environmental factors. For many autoimmune diseases the main 
genetic factors associated to the pathogenesis are the genes encoding the 
HLA complex. The genic area encoding for HLA complex, contain at 
least 128 genes, locate on chromosome 6, most of which (40%) are 
immune-genes. This genic complex is characterized by high gene 
density, and by strong linkage disequilibrium (8). 
First celiac disease genetic studies, performed in the 70's, reported an 
association of disease with HLA Class I A*01 and B*08 genes (9, 10), 
only later studies associated the disease to HLA DQ2 and DQ8. HLA A1 
and B8 molecules are found in strong linkage disequilibrium with HLA 
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Class II HLA-DR3-DQ2 that leads to the extended haplotype HLA A1-
B8-DR3-DQ2. Aly and co-workers found that in this haplotype 
(spanning on a region of 2.9 Mb of MHC), HLA DQ2-DR3 are more 
conserved when associated to B8 than to A1 (11). 
Since the early studies of genetic association, this extended haplotype 
has been found associated to several diseases including severe form of 
sclerosis (12). So, over the years it has been associated to high risk to 
develop multiple (auto)-immune diseases (Type1 diabetes (T1D), 
systemic lupus erythematosus, common variable immunodeficiency, 
HIV etc (13-17).  
Despite that, genetic studies results about A1-B8-DR3-DQ2 and its 
involvement in celiac disease are long and complex, and often 
inconsistent (17-19). It‟s known that primary association of disease 
seems to be with HLA DQ2-DR3, but genetic susceptibility to celiac 
disease could be due to more than just HLA DQ2/DQ8 positivity, but 
also by the presence of other genes not identified yet, and HLA A1 or B8 
could be one of these.  
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This haplotype was associated to different dysfunctions of immune 
system also in healthy controls. In particular, is responsible for an altered 
production of cytokines that lead to decrease of lymphocyte T helper 1 
responses, and to the increase of T helper 2 responses (20-21). This 
unbalanced immune “responses” could be related to increase of risk to 
develop autoimmune disease by subjects carriers of this haplotype.  
Despite that a clear and unique in vitro association of celiac disease to 
HLA class I A1 and B8 is not be demonstrated yet. 
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1.2 AIM  
Aim of this project is to identify gliadin peptides able to activate a 
specific adaptive immune response restricted by HLA Class I A1 and 
B8. In particular we aimed to assess the frequency of CD8
+
T cells 
specific for the identified HLA class I A1/B8- restricted epitopes in 
celiac patients. Also we investigated the frequency of extended 
haplotype A1-B8-DR3-DQ2 in our cohort of celiac volunteers.  
 
The project proposed in this study comprises the following experimental 
phases:  
 Typing of the HLA Class I A and B loci in celiac patients and 
non-celiac controls (for the selection of the study population). 
 Typing of HLA Class II DR and DQ loci 
 Identification of gliadin peptides that selectively bind to HLA 
Class I A*0101 or B*0801 molecules. 
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 Function assays to assess the immunogenicity of a panel of gliadin 
peptides selected on the base of their binding affinity to HLA 
A1/B8 in Celiacs. 
 Further investigation of phenotype and function of T cells specific 
for immunogenic peptides by generating long term cytotoxic T 
cell lines. 
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1.3 MATERIALS AND METHODS 
1.3.1 Study population and HLA class I and II typing 
Population study was composed by 106 adult and young celiac patients 
(mean age 21.34- range 4-65), and by 35 healthy controls. All subjects 
were recruited in South Italy areas, the adult ones at “Moscati” Hospital 
of Avellino, while the young ones at the “Section of Pediatrics”, 
Department of Translational Medical Science, of University of Naples 
“Federico II” (Table 1.3.1). All patients or their parents, in the case of 
children gave full informed consent to the experiments. Celiac patients 
received diagnosis of celiac disease in conformity to ESPGHAN 
(European Society for Pediatric Gastroenterology Hepatology and 
Nutrition) criteria. All celiac were on gluten-free diet (GFD) for at least 
2 years, and were serum negative for anti-tTG and antiendomysium Ab 
(EMA).  
From peripheral blood sample of participants were obtained peripheral 
blood mononuclear cells (PBMCs). T cells blast were generated 
following polyclonal stimulation of PBMCs with 0,5g/ml 
phytohemagglutinin (PHA) (Roche, Basel, CH), then DNA were 
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extracted using commercial (Genomic DNA Miniprep kit, Sigma-
Aldrich, St. Louis, MO) kits. 
Pure genomic DNA was used to serologically typing for HLA class I A1 
and B8 (HLA A and HLA B Low Res-AllSet Gold SSP), and class II 
(DRB1 and DQB1), using commercial Kit (AllSet
+
SSP kit) (Life 
technologies, Carlsbad, CA). These kits are based on PCR method and 
use HLA specific oligonucleotide sequences as probes. 
Twenty-four celiacs (mean age 23-range 5-45) within the HLA A1 or B8 
positive population were enrolled for functional immunogenicity assays. 
Peripheral blood sample were collected to obtain PBMCs used in these 
assays. 
In addition sixteen donor blood volunteers who result HLA A1
+ 
and/or 
B8
+ 
after either both flow cytometry (mAb Anti-HLA Class I B8, and 
A1-A36, Abcam, Cambridge, UK) and serological typing were selected. 
PBMCs derived from these subjects were used for functional assays.  
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Table 1.3.1: Celiac patients enrolled in this study 
 
1.3.2 Identification of candidate HLA A1 or HLA B8-resticted gliadin 
peptides 
The entire amino-acid sequence of 2 -, 2 - and 2 -gliadins (Gene-
Bank) were analyzed using bioinformatic algorithms to identify the 
presence of HLA A*01 and HLA B*08 binding motif.  
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The binding motif of HLA A1 is S or T in position 2 and/or D and E in 
position 3, with Y at the C-terminus, while the binding motif of B8 is R 
or K in position 3 and/or 5, with L, I, V, M or F at the C-terminus (22). 
This analysis has provided a certain number of gliadin peptides, 
predicted to have different binding affinity to the HLA A1 or B8 
molecule. 97 of them showed high affinity (Binder threshold<IC50nM) 
and were selected for additional experiments.  
These peptides were first synthesized and then purified using reverse-
HPLC technique. Following synthesis, the „purity‟ and „identity‟ of 
peptides were confirmed using analytical reverse-HPLC and mass 
spectrometry. 
 
1.3.3 Binding assay to purified HLA-A1 and B8 molecules 
Next we confirmed the binding affinity for HLA A*0101 and for HLA 
B*0801 using an in vitro quantitative inhibition assay, based on purified 
HLA molecules and iodinated probe peptides. 1-10 nM of tested peptides 
iodinated were co-incubate 2hr at room temperature with purified HLA 
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A1 and HLA B8 molecules (obtained from EBV transformed cell lines 
Steinlein), in presence of 1 M of 2-microglobulin and protease 
inhibitor. 
The unbound probe peptide fraction was separated from whole complex 
peptide/MHC class I by gel filtration and then quantified, to give a 
measure of the binding affinity.  
The screening and synthesis of peptides were performed by the research 
group of Dr Alessandro Sette at La Jolla Institute for Allergy and 
Immunology, San Diego (CA). 
 
1.3.4 EliSpot Assay  
Peptides specific T cells response was observed using IFN- EliSpot 
Assay on freshly PBMCs. Gluten-specific T cell responses were 
observed using this assay on PBMCs, obtained by patients‟ peripheral 
blood samples.  
PBMCs were isolated from heparinised whole blood using Ficoll (Ficoll-
PaqueTM PLUS, GE Healthcare, UK) gradient separation. Cells (2x10
5
)
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were seeded in duplicate in complete medium [X-Vivo (Lonza, Basel, 
CH) enriched with 5% of heat inactivated Human Serum (Lonza, Basel, 
CH), 1% L-glutamine (2mM, Lonza, Basel, CH), and 1% Penicillin-
Streptomicin (Lonza, Basel, CH)], on a 96 wells nitrocellulose backed 
plate (MAHA S4510- Millipore, Bedford, MA). Plates were pre-coated 
with anti (10g/ml) IFN- mAb (Mabtech, Cincinnati, OH) over-night at 
4°C in coating solution (NaHCO3 50mM/ Na2CO3 50mM).  
Following cells incubation, plates were incubate with biotinylated anti-
IFN-Mabtech, Cincinnati, OH) for 2h at room temperature. Thereafter 
plates were washed with PBS-0,05% Tween20 (Sigma-Aldrich, San 
Louis, MO) and then were incubated with Streptoavidina HRP (BD-
Pharmingen, Franklin Lakes, NJ) in a diluition buffer (PBS1X/BSA1%) 
(Sigma-Aldrich, San Louis, MO) for 1hr at room temperature. Following 
the addition of aminoethyl carbazole (AEC, Sigma-Aldrich, San Louis, 
MO) solution for five minutes, cytokines releasing cells can be detected 
as single spot using ELISPOT image analysed (A.EL.VIS, Hannover, 
Germany) 
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1.3.5 Generation of CTL lines from PBMCs 
To generate CTLs, 4x10
6
 freshly PBMCs were plated in 1 ml of 
complete medium [(X-Vivo (Lonza, Basel, CH) enriched with 5% HS 
(Lonza, Basel,CH), 1% L-glutamine (2mM) (Lonza, Basel,CH), and 1% 
Penicillin-Streptomicin (Lonza, Basel, CH)] in presence of peptides 
(6g/ml). At day 7 cells were re-stimulated with (2-3x106) autologous 
mononuclear cells (as described below), previously pulsed with gliadin 
peptides (6g/ml). Interleukin 2 (R&D System, Minneapolis, MN) 
40U/ml was added to feed cells every three days. 
At 19-21 days after culture set-up, CD8
+ 
cells were separated from bulk 
culture using MACS immune-magnetic separation, according to 
manufacturer‟s protocol (Miltenyi, Bergisch Gladbach, Germany)  
 
1.3.6 Generation of mononuclear cells from PBMCs & T cell Assay 
To generate mononuclear cells at day 7 subsequent to generation of 
CTLs, autologous irradiated PBMCs were seeded at 2-3x10
6
 cells in 1ml 
in a 24 plate, and incubated for 2hrs at 37°C and 5% CO2. Non adherent 
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cells, were removed by washing twice with PRMI 2% HS [1% L-
glutamine (2mM) (Lonza Basel, CH), and 1% Pen/Strep (Lonza, Basel, 
CH)]. Mononuclear cells were pulsed with peptides (6g/ml/peptides) 
for 2hrs at 37°C and 5% CO2, in 1ml of complete medium enriched with 
3ug/ml2-microglobulin (Calbiochem, San Diego, CA). After the 
incubation non adherent cells are removed from the plate, by twice 
washing, and CTLs previously collected are added to the mononuclear 
cell layer.  
At 19-21 days after generation, CTLs and CD8 positive cells (3x10
5
 
cells) were assayed using IFN-EliSpot and/or ELISA to analyze 
immune response to gliadin peptides. Autologous PBMCs or HLA 
matched EBV (1x10
5
/well) pulsed ON with gliadin peptides (10g/ml), 
in presence of -microglobulin (3g/m, Calbiochem, San Diego, CA), 
were used as APC. 
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1.4 RESULTS 
1.4.1 Identification of the study population 
In order to investigate the role of HLA class I A*01 and B*08 alleles in 
celiac disease, and to identify gliadin epitopes restricted by HLA class I 
A1/B8 molecules, we screened volunteers with celiac diseases or healthy 
donor. To assess the frequency of HLA Class I A*01 and B*08 alleles 
our selects subjects, carrying the HLA Class I A*01 and/or B*08 alleles, 
were submitted to a complete HLA Class I and II genotyping.  
Results of HLA class I typing have shown that overall 42,4% celiacs 
results HLA A1 and/or B8 positive. In particular patients A1
+
/B8
-
 were 
18,9%, while patients A1
-
/B8
+
 were 9,4% and A1
+
/B8
+
 patients were 
14,1%.  
After HLA class II typing we found that frequency of DR3-DQ2 is 42%. 
Among our DR3
+
 the 65,4% of subject were A1 and/or B8 positive, in 
particular the A1
+
/B8
-
 subject are the 7,69%, the A1
-
/B8
+
 subject are the 
26,92%, while the A1
+
/B8
+
 are 30,77%.  
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These results seem to be in accordance with previously published data, 
that showed a preferential association of HLA class I A1 and B8 to HLA 
class II DR3 (13).  
 
1.4.2 Identification of HLA-I A1 or B8 restricted gliadin peptides 
Following the identification of a population study, we have attempted to 
identify gliadin toxic epitopes, potentially recognized by HLA class I A1 
and/or B8, using the already known binding motifs to HLA Class I A1or 
to B8, molecules (22). 
The screening of the entire aminoacid sequence of 2 -, 2 - and 2 -
gliadins, provided hundreds of peptides, candidate epitopes A1/B8 
restricted. We have chosen 97 peptides of 9-10 aminoacid lenght with 
the highest score of binding (data not shown). 
Predicted peptides mapped in all gliadins examined (alpha-, gamma- and 
omega-gliadin). 24/97 (24,7%) were found in the omega gliadins, 25/97 
(25,8%) in the alpha gliadins and 48/97 (49,5%) in the gamma gliadins.  
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Of all peptides identified 47 (48,45%) are potential HLA A1 binder, 47 
(48,45%) HLA B8 binder, and 3 (3%) were predicted bind both HLA A1 
and B8 molecules.  
All peptides were synthesized, and following quantitative inhibition 
assay, it has been demonstrated that only 23 peptides 23,7% (23/97) had 
a significant thresholds binding affinity (IC50<500nM) to purified HLA 
class I molecules (Table 1.4.1). 
 
Table 1.4.1: List of gliadin peptides with the highest score to bind HLA class I A1+ or B8 
molecules 
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In particular 3/97 (3,1%) peptides have shown significant affinity to 
HLA A1 purified molecules, while 20/97 (20,62%) to purified HLA B8 
molecules.  
These 23 peptides have been used for additional experiments. 
 
1.4.3 Immune response to HLA A*01 and B*08 restricted peptides in 
peripheral blood cells 
Following identification and synthesis, we assayed the immunogenic 
properties of selected peptides. In particular, we assessed the ability of 
PBMCs derived from celiac and healthy volunteers HLA A1 and/or B8 
positive and celiac A1/B8 negative to recognize peptides, using IFN- 
EliSpot Assay. 
Each of the 3 A1 binder peptides were assayed in celiac (both HLA A1 
positive and HLA A1 negative), and A1 positive healthy controls. 
Results were shown as Net IFN--SFC/106 cells. The means plus 2SD of 
this value for each A1 peptides were calculated in HLA A1 negative 
celiac patients. The responses of each patient were considered positive 
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when exceeding these values. We considered the positive response 
significant, when it was detected in at least 3 patients. 
As shown in figure 1.4.1 p158-167 derived from -gliadin stimulated the 
activation of INF-γ secreting cells in 4/8 celiac A1+, corresponding to 
50% of responders‟ population. 
Also we found a significantly IFN- production in response to p414-423 of 
-gliadin in three/8 patients corresponding to 37,5% of population.  
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Figure 1.4.1: Gliadin-specific IFN--releasing cells detected in PBMCs of HLA-A*01 positive and 
negative celiac patients and healthy controls in response to HLA class I A1 peptide p#1(A) and p#2 
(B). Red lines indicate the mean plus 2 standard deviations of responses from A1
-
 negative celiac 
subjects. 
 
In no cases a significant response was observed in healthy controls.  
All these data demonstrated that 66,65% of HLA A1 restricted peptides 
resulted able to activate an immunogenic response in PBMCs in at least 
3/eight celiac. 
Same responsiveness criteria were used to select positive HLA B8 
restricted peptides.  
PBMCs of both celiac and healthy controls cells were assessed towards 
twenty HLA B8 binder epitopes (Fig.1.4.2).  
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Results have shown that seven HLA B8 peptides (p#10, p#12, p#13, 
p#16, p#17, p#20, p#23) stimulate PBMCs, in at least three B8 positive 
celiac, corresponding to 23,07% of population to produce IFN-. In no 
cases we found a positive response to these peptides by healthy controls.  
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Figure 1.4.2: Gliadin-specific IFN--releasing cells in response to HLA class I B8 peptide [p#10(A), 
p#12(B), p#13(C), p#16(D), p#17(E), p#20(F), p#23(G)]. Results are shown as Net IFN--SFC/10
6
 
cells. Red lines indicate the mean plus 2 standard deviations of responses from B8
-
negative celiac 
subjects 
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Peptide p286-294, stimulated responses in eight/13 celiac corresponding to 
61,54% of population. Responses of healthy control HLA B8 were not 
significant (fig1.4.3).  
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Figure 1.4.3: Gliadin-specific IFN--releasing cells in response to HLA class I B8 peptide (#21). 
Results are shown as Net IFN--SFC/10
6
 cells. Dash lines indicate the mean plus 2 standard 
deviations of responses from B8
-
negative celiac subjects 
 
These data indicated that 34,8% of restricted B8 peptides stimulated an 
immune response in PBMCs of B8 celiac.  
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25% (2/8) of all immunogenic peptides derived from -gliadin, 12,5% 
(1/8) derived from -gliadin, while the rest (62,5%-5/8) derived from 
-gliadin.  
Overall these data demonstrated that different gliadins have 
immunogenic peptides able to recall a secondary immune-response in 
PBMCs of celiac with HLA class I A1 or B8.  
 
1.4.4 Immune response to HLA A*01 and B*08 restricted peptides in 
fresh peripheral blood cells 
To further analyze the response obtained, we summarized in table 1.4.2 
the profile of peptides recognition for each A1 patients. Of all A1 
positive selected patients five/8 were responders. Patients P5 and P8 
were found reactive to both A1 immunogenic epitopes, while P1, P6 and 
P7 recognized only one/2 immunogenic peptides. Three celiac were not 
reactive to any peptides. The 60% of responders results DR3
+
. 
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Table 1.4.2: Profile of recognition of HLA A1
+
 restricted peptides in celiac patients 
 
In table 1.4.3 is shown the profile of responses to HLA B8 peptides by 
celiac B8 positive. As for A1 responders, the responses to B8 epitopes 
were heterogeneous among 9/13 responders, despite two patients gave a 
significant response to almost all immunogenic peptides. About 67% of 
responders were DR3
+
. 
 
Table 1.4.3: Profile of recognition of HLA B8
+
 restricted peptides in celiac patients 
 
1.4.5 Immune responses to HLA A*01 and B*08 restricted peptides in 
CTLs  
Next we investigated the nature of responses obtained. In particular we 
generated cytotoxic T cells stimulating in vitro PBMCs, from two B8 
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positive patients, with a pool of immunogenic B8 epitopes, whose 
response results positive by previously functional assays. Next we 
evaluated IFN- secreting cells in response to mentioned above peptides, 
and also performed the assays on bulk culture, and on purified CD8
+ 
cells, obtained following immunomagnetic CD8 separation.  
In figure 1.4.5 is shown the representative response obtained in patient 3 
in response to gliadin, and to p224-232 peptide and to p11-19 peptide. Results 
were shown as Net IFN- secreting cells.  
 
Figure 1.4.5: Net IFN-/SFC 10
6
 obtained on bulk culture, and on CD8
+
 T cells purified with magnetic 
beads in response to gliadin and to p11-19 and p224-232 peptide. 
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Results have shown that in bulk culture net IFN- secreting cells were in 
response to p11-19 in the range 166,5-110/10
6
 (mean 133/10
6
±47), in 
response to p224-232 in the range 3496-399/10
6 
(mean1948/10
6 
±2189). 
Following immunomagnetic separation we found net-IFN- secreting 
cells were in response to p11-19 in the range 6327-4628/10
6 
(mean 
5477,85/10
6 
±1200), in response to p224-232 in the range 11255,4-8891/10
6
 
(mean 10073,25±1671). 
In addition we performed a phenotypic analysis of these two cell 
populations. In one of this case in bulk culture 51,91% of population is 
composed by CD3
+
CD8
+
 cells, and this population contains ~0,01% 
(133,25/10
6
) p11-19 responsive cells, and ~0,2% (1948/10
6
) p224-232 
responsive cells Following immunomagnetic separation we found that 
CD3
+
CD8
+
 became 93,92%, and the percentage of p11-19 responsive cells 
increase up to ~0,55%, while p224-232 responsive cells became ~1% .  
Phenotypic analysis confirmed that these immune-responses were 
mediated by CD8
+
 cells.  
Overall these data indicated that in peripheral blood of celiac, specific 
CTLs produced IFN- in response to peptides restricted by HLA class I. 
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1.5 DISCUSSION  
Celiac disease is an auto-immune disorder in which both innate and 
adaptive immunity are involved. It has been widely characterized the 
role of CD4
+
T lymphocytes in the mucosa damage, and the involvement 
of HLA class II DQ2/DQ8 in the disease (23). In fact, it has been 
recently identified the complete repertoire of the immunogenic gluten 
peptides and the immune-dominant epitopes, eliciting a CD4
+
T cells 
response (24).  
There is a general consensus on the key role of CT8
+
T lymphocytes, 
massively infiltrating intestinal mucosa of all celiac disease forms, in the 
villous atrophy. In particular, this prominent pathogenic function was 
mainly attributed to the intraepithelial CD8
+
T lymphocytes of the innate 
immunity branch (25). These CD8
+ 
IELs would be armed to kill 
enterocytes after gluten exposure, through a mechanism TCR-
independent. Despite that, very little is known about the role of adaptive 
T CD8
+
 lymphocytes, and the possible involvement of HLA Class I 
molecules in CD pathogenesis is not completely clarified.  
58 
 
First evidences have demonstrated that gliadin contains a peptide able to 
activate adaptive CD8
+
T lymphocytes exclusively in celiac disease 
patients. This peptide mapping the 123-132 sequence of α-gliadins is 
restricted by the HLA Class I A2 molecule and is specifically recognized 
by HLA-A2 positive CD subjects. However, there is no strict genetic 
association with HLA A*0201 gene, since it is carried by almost 30-40% 
of celiac subjects, a percentage non different from that of the general 
Caucasian population (26).  
In the present study, we have expanded the analysis to A*01 and B*08, 
two other HLA Class I alleles usually present in Caucasian population. 
We reported that several gliadin peptides with high binding affinity to 
HLA class I A1 and B8 molecules are able to stimulate a CD8
+
T cell 
response in celiac patients A1/B8 positive. 
In order to explore the role of HLA class I restricted CD8
+
 T cells in CD, 
we have screened the entire sequences of two - two - and two -
gliadins, for the presence of peptides predicted to bind A1 and B8 
molecules using bioinformatic algorithms available from the IEDB 
(www.iedb.org) based on A1 and B8 binding motifs. 
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Remarkably, our results demonstrated that all families of gliadin (-, -, 
and -gliadins) contain hundreds of peptides potential binder to A1 and 
B8. The top 1% scoring 9- and 10-mer peptides were synthesized and 
tested in MHC-peptide binding assays using purified A*0101 and 
B*0801 molecules. Overall, 23 peptides had an high in vitro affinity, and 
in particular, three peptides bound HLA A1, while the other twenty 
bound HLA B8 and were selected for immunogenic assays.  
We demonstrated that ten gliadin epitopes restricted by HLA class I A1 
(two peptides) and B8 (eight peptides) recall a secondary immune 
response in PBMCs of celiac patients under treatment. Further, for two 
peptides (p11-19 and p224-232) the cells involved in the induction of 
response were CD8
+
T lymphocyte.  
In both conditions the activation of immunonogenic pattern was 
evaluated measuring IFN-secreting cells. IFN-represent one of most 
pro-inflammatory cytokines involved in the intestinal damage (27).  
In addition genotyping results confirmed in our Campania population the 
strong association of HLA class I A1 and B8 to HLA class II DR3. 
60 
 
Interestingly, functional assays revealed a very heterogeneous 
recognition pathway among CD volunteers, since we have not found a 
prevalent response towards a specific peptide(s). By contrast, we 
observed that each of 23 different peptides were recognized by at least 
one CD patients (data not shown). To avoid any bias, our cut-off was 
very selective. We calculated means plus 2SD of Net- SFC/106 cells 
obtained in celiac negative for HLA class I A1 and B8. The responses to 
each peptide were considered positive when exceeding these values. We 
considered immunogenic those peptides that gave a positive response in 
almost 3 of tested patients. 
On the base of our criteria of positive response, we verified that two of 
HLA class I A1 restricted peptides (p158-167 and p414-423) corresponding to 
66,65%, and eight of HLA class I B8 restricted peptides (p11-19,  p224-232, 
p22-30, p213-222, p1-9, p287-295, p286-294 and p203-211), corresponding to 34,8%, 
can recall a T cell responses in peripheral blood cells of celiacs 
respectively A1 and B8 positive, and can be considered immunogenic. 
However peptide p158-167 derived from -gliadin and restricted by HLA 
A1, and peptide p286-294 derived from γ-gliadin, and restricted by HLA 
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B8, results more immunogenic than other. p158-167 activated a T cell 
response in 50% (4/8) of A1
+
 celiac, while p158-167 in 61,54% (8/14) of 
HLA B8
+
 patients. We hypothesized that these two peptides could be 
presented by HLA class I molecules more easily and strongly than other, 
and they have more immunogenic sequences than other peptides. 
Also, in our T cell responses we have not found any significant response 
by PBMCs of healthy controls, enrolled on the base of their positivity for 
A*01 or B*08 alleles, to any candidate gliadin peptides. One exception 
was represented by one healthy control whose response to p224-232, 
exceeded the cut-off values. We hypothesized that this subject (HLA A1
-
B8
+
) could be a case of undiagnosed celiac disease, or the activation of 
immune-response could be a consequences of cross-reactivity to this 
peptide by different HLA Class I (for example by A36, B35 and/or B62).  
Many studies concerning prediction of binding, have asserted that 
binding affinity correlates with immunogenicity (28-30). Sette and 
coworkers have shown that 50% of all high-affinity binders identified in 
an HLA A*02 mouse systems are immunogenic (31). In our study we 
found, in accordance with these data that among 23 epitopes selected for 
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functional assays, based on high binding affinity to HLA class I 
molecules, ~43% results immunogenic. These data confirmed that 
binding analysis provided a great advantage in identification of peptides 
potentially epitopes of T cells.  
By itself these results were important because they show for the first 
time that gliadins have sequences potentially binders to HLA A1 or B8. 
Importantly, genes coding for A1 and B8 heterodimers are part of an 
extended haplotype represented by HLA A1-B8-DR3-DQ2 that is 
associated with several autoimmune disease (such as Systemic lupus 
erythematousus, diabetes mellitus, ecc) (13). 
Results of screening showed that -gliadins contains the highest number 
of peptides binding to HLA class I than the other two gliadins 
(approximately 49,5% of all predicted peptides, compared to % 25,7% of 
alpha and 24,7% of omega). In addition, results obtained with in vitro 
binding assays (52,17% were gamma-gliadins compared to 21,7% of 
alpha, and 26% of omega), and with functional assays (50% of all A1 
and B8 immunogenic peptides derived from gamma-gliadins compared 
to 37,5% from omega, and 25% from alpha gliadin), confirmed that 
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HLA class I preferentially presented -gliadin peptides. These data could 
indicate that -gliadin play an important role in the immune-pathogenesis 
of celiac disease, in accordance to previous studies indicating the high 
immunogenic properties of some -gliadin peptides on CD4+T cells (32). 
In order to exclude that the activation of immune response was the 
results of presentation of gliadin peptides by HLA DQ2 molecules, we 
screened the sequences of all peptides for the presence of consensus 
sequence for binding to DQ2/DQ8. It‟s known that binding motif sites to 
HLA class I A1 and B8 are very different to binding motif sites of HLA 
class II DQ2/DQ8 (with a E in position 4, 6, 7 for DQ2 and E in position 
1 and 9 for DQ28). We found that among all A1 and B8 binders peptides 
analysed in our study, only two had classical QXP site (FPQQQRPFI 
restricted by HLA B8, and VSFQQPQQQY restricted by HLA A1) and 
could determinate a cross-reactivity response. However, we have not 
found an in-vitro significant immunological response by PBMCs to both 
this peptides, thus excluding any immune activity in our celiac patient 
cohort. 
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Next, we further investigated the phenotype of PBMCs reacting to 
immunogenic peptides by generating short-term cytotoxic CD8
+
T cell 
lines, raised toward the most active epitopes. Our results have shown that 
two peptides p11-19 and p224-232 were able to stimulate specific CTLs to 
produce IFN-. Phenotypic analysis confirmed that CD3+CD8+ cells 
mediated these responses, as established by ~41 fold increase in IFN- 
levels obtained in purified CD8 cells in response to p11-19, and by ~5,2 
fold increase obtained in response to p224-232.  
The low frequency of specific cells (from <0,001% to 0,1%), could be 
explained by the fact that we have analysed response in peripheral blood 
of subjects on gluten free diets. It is most likely that the frequency of 
these cells could be much higher after a short gluten challenge. In 
concordance with this hypothesis, Han and co-workers (55) found an 
increase of CD8++ cells from <0,1% in basal condition (day0) to 1,2% 
(day6) following gluten challenge along with an increase of ++ cells 
(from <0,1% at day 0, to 6,8% at day 6).  
Overall these data shown that gliadin peptides were able to stimulate 
PBMCs or cytotoxic cells to produce IFN-and for this reason could 
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contribute to activation or maintenance of immune-response and so 
contribute to intestinal damage.  
Interesting it‟s widely demonstrated by several studies the involvement 
of cytotoxic cells in the pathogenesis of different autoimmune disease.  
Extensive evidences have demonstrated the role of cytotoxic CD8
+
T 
cells and HLA class I in diabetes. Many studies have shown these 
evidences in mouse model. It has been clarified that Nonobese mouse 
model (NOD) null for expression of 2-microglobulin lack the ability to 
develop insulitis and diabetes in NOD mouse (33, 34). Unlike when 2-
microglobulin was deleted only from -cells the progression of disease 
was decrease (35). 
Cytotoxic cells were also involved in human T1D and in islet allograft 
rejection. Islet infiltrating pancreatic cells was predominantly CD8
+ 
(36). 
These evidences were reinforced recently when CD8
+
 cells were 
evidenced in the islet of organ donors who are positive for islet cell auto-
antibodies (37). 
Further in vitro evidences have established that human -cells were 
destructed by CTL in MHC specific manner (38).  
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Coppieters et al, has shown first evidences of presence of islet-reactive 
CD8 T cells in insulitic lesions from patients with recent-onset and also 
longstanding T1D, confirming their role of these cells in progression of 
disease (39). 
In contrast several auto antigens epitopes recognized by CD8
+
T in 
diabetes, were identified in proinsulin, (40, 41), glutamic acid 
decarboxilase (GAD) (42) and glucose 6 phospatase catalytic subunit 
releted protein IGPRP. 
Autoreactive CD8 T cells play a role moreover in Multiple Sclerosis 
(MS) since expansions of CD8 T cells were found in the blood, and in 
the cerebrospinal fluid of MS patients (43), suggesting that myelin 
antigens can indeed be recognized by human MHC class I-restricted 
CD8 T cells. 
Our results were in accordance with overall these evidences, these data 
boost to carry on in the investigation of CD8
+
T cells role in celiac 
damage, since only recently has been posed attention on involvement of 
this bunch of adaptive immunity.  
Results of genotyping have shown that among our celiac population the 
frequency of HLA A1 or B8 were 42,5%, but interesting, among our 
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DR3
+
 the percentage increase to 65,4%. Experimental results have 
shown that among all celiac responders the 58,8% results to be DR3
+
, 
while the rest were DR5/DR7, with only one exception represented by 
one celiac DR4/DR8. All these data underlay the linkage of A1 and B8 
to DR3. Our findings were consistent with previously published data that 
demonstrated the involvement of this haplotype in the immune mediated 
response in patients with celiac disease (13).  
In this project we decided to identify gliadin epitopes potentially 
recognized by CD8
+
 cells. At the presents only few previously studies 
demonstrated the involvement of T CD8
+
 lymphocyte TCR dependent 
response in celiac disease. In particular as mentioned already Gianfrani 
and co-workers demonstrated that, in celiac patients with HLA class I 
A2 positive celiac, the peptide 123-132 of A-gliadin, induced a T CD8
+
 
cell response responsible of tissue damage.  
It known that first celiac disease genetic association studies reported an 
association of disease with HLA Class I A*01 and B*08 genes (9, 10). 
HLA A*01 and B*08 are often related in the auto-immune haplotype 
HLA A1-B8-DR3-DQ2. This haplotype is highly conserved, and, as 
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widely demonstrated, was found associated to high risk to develop 
multiple autoimmune disease (13).  
This genic complex, including HLA A1-B8-DR3-DQ2, is characterized 
by high gene density and by strong linkage disequilibrium (11) 
responsible for the transmission of the extended haplotype.  
As mentioned above, the genetic study results, about this haplotype, are 
often inconsistent. A previously study showed in Spanish children 
population that among HLA A-B-C, the A1-B8-Cw7 haplotype (A19-
B12-Cw7/A1-B8-Cw7), and among HLA A-B-DR, A1-B8-DR3 
haplotype results most frequent in celiac than healthy controls (17).  
In addition the haplotype B8-DR3-DQ2 was found over-expressed (44) 
in patients with atypical form of celiac disease than the other. In patients 
with both, celiac disease and type 1 diabetes, has been demonstrated that 
this haplotype is more frequent in celiac, and, B8 is main risk factor to 
develop celiac disease presents in this haplotype (18). B8, in fact, 
contributes to increase of approximately four fold the CD development 
risk given by DR3-DQ2 (fundamental to CD development) both in 
Italian and Finnish (18). 
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HLA B8 probably is crucial for antigen basic for development of 
disease, as confirmed by demonstration of major association of this HLA 
to CD patients than diabetes. B8 is major risk factor in the haplotype and 
contribute to develop of disease more than other HLA class II genes.  
We identified more immunogenic peptides binder to HLA B8, than A1. 
These features could be related to higher risks to develop disease 
associated to HLA B8 than A1. 
For all this reason in this project we decided to evaluate the role of this 
extended haplotype, looking at the genetic penetrance of HLA A*01 
and/or B*08 alleles in our population study. This might be useful to help 
to understand the genes involved, and better characterize the genetic risk 
of celiac disease, and the immune mediated mechanisms responsible for 
the development of disease.  
In future will be important to further characterize the role of CD8
+
T cell 
mediated responses in this disease, for example to evaluate if these cells 
produce IL-21 and IL-17, two cytokines modulated (45) in celiac 
disease, and to investigate whether HLA A1/B8 restricted CD8
+
 T 
lymphocytes contribute to the lesion of intestinal mucosa of CD patients. 
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Through this research project we aim to better characterize the 
involvement of the adaptive lymphocyte response mediated by CD8
+
T 
cells in celiac disease. Only if we identify all immune mechanism of 
disease, we can image and design a new therapy.  
The characterization of toxic fractions of gliadin, capable of generating a 
lymphocyte response in patients with HLA class I A1 and/or B8, would 
allow a better understanding on the molecular mechanisms responsible 
for the development of small intestinal lesions.  
This study could be useful to confirm the role of genetic risk of the 
extended haplotype DR3-DQ2-A1-B8 in developing celiac disease. This 
information could be important to allow risk stratification in family with 
first degree relative with the celiac disease. 
This project could provide new insights into the genetic and 
immunological components responsible for the development of celiac 
disease, which at the time, have not been fully clarified yet. 
Given the strong linkage disequilibrium of A*01 and B*08 with the 
DR3-DQ2 haplotype, and the immune-stimulatory properties of A1 and 
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B8 gliadin peptides, the potential role of A1 and B8 gene/molecules in 
CD pathogenesis should be revaluated.  
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CHAPTER 2 
Repertoire of epitopes recognized by CD4 T cells in children with early 
or overt celiac disease.  
2.1 INTRODUCTION 
2.1.1.  Is celiac disease different among adults and children? 
It has been reported that clinical manifestations are different among adult 
and children with CD. Vivas and co-workers have suggested an age 
related pattern in clinical presentation of CD, since the disease presents 
with more pronounced symptoms, and with a severe villous atrophy in 
young children (1). Younger children, also, present with abdominal 
complaints, bowel movement disorder, and pronounced GI symptoms 
than older children with CD (2). By contrast, both atypical and silent 
forms present similar clinical manifestations among the different age 
related groups (2), with exception of anemia that is prevalent in adult, 
whilst the short stature is more prevalent in children and dermatitis 
herpetiformis affects mostly adults (3).  
Furthermore, children with CD show a faster resolution of the 
inflammatory and intestinal damage upon gluten free diet, and have a 
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reduced risk to develop complications, such as autoimmune disease in 
comparison to adults (4). In fact, the association of CD with auto-
immune disease varies in age related manner, and it has been found a 
positive correlation of auto-immune diseases incidence with the age of 
CD diagnosis (5-7). This may be related to duration of gluten exposure 
until diagnosis (7). One of the key questions is whether the differences in 
clinical phenotype between children and adult celiac subjects depend on 
differences in the immunological response to gluten.  
Since the time elapsed from the development of disease to clinical 
diagnosis may vary in the order of weeks, months up to many years, it is 
not possible to characterize the primary immune response to gluten, 
particularly the repertoire of gluten peptides inducing the primary T cell 
activation in CD mucosa. However it is possible to investigate the 
secondary memory T cell responses generated in celiacs at the different 
disease stages (8, 9). Several experimental approaches including long-
term T cell lines (TCLs) and T cell clones (TCCs) raised from small 
intestinal mucosa or peripheral blood responses after gluten oral 
challenge have been used to identify the stimulatory gluten sequences 
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(10). It has been demonstrated that the great majority of CD4 T cell-
mediated immune responses from adult celiac patients were directed 
against gluten peptides when deamidated by tissue transglutaminase 
(TG) (11). Since the activation of deamidase activity by TG2 enzyme is 
strongly increased by the inflammatory tissue process, one question is 
related to the role of TG activity in the first disease stages of CD both in 
adults and young subjects with CD. To date, only one study has analyzed 
the pattern of CD4+T cell reactivity to gluten peptides in a cohort of 
very young HLA DQ2
+
 Dutch patients (8). This study showed a 
substantial heterogeneity of intestinal T cell responses to gluten peptides 
with a large proportion of responses directed to both deamidated and 
wild type gliadin, and with the identification of six novel epitopes. 
Importantly, Vader and coworkes showed that for three of these novel 
epitopes, tTG-mediated deamidation was not required for the cell 
stimulatory properties, suggesting that, at least in children, the peptide 
immune activity is independent by deamidation. 
Based on these features, it has been hypothesized that in celiac patients, 
the adaptive T cell response can be primed by naive peptides, and 
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subsequently, it is driven toward immunodominant deamidated 
sequences. It could be envisaged that the recognition of few native 
peptides, at the site of small intestinal mucosa, may trigger the 
production of inflammatory cytokines, as IFN- and activate an 
inflammatory loop resulting in tissue damage and TG2 release. As 
consequence, the CD4
+
T cell response is strongly enhanced with more 
IFN-production and increased release of TG2. Alternatively, other 
factors, such as infections occurring in the gastrointestinal tract, may 
trigger the inflammatory response to naive gluten peptides and the 
activation of TG2 (8, 10). 
In order to investigate the immune response activated in the early stage 
of disease, a good model may be represented by potential celiac disease. 
Potential celiac disease is a condition characterized by a positive 
serology for the tissue transglutaminase autoantibodies (tTG2), but a 
normal morphological duodenal mucosa or with slight signs of 
inflammation (12). It has been observed that almost 10% of children 
with positive serology have potential CD and only 33% of them develop 
the overt disease after 3 years (13). It‟s not clear if potential celiac 
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disease represents a preclinical condition that affect all celiacs, or if it is 
different form of disease.  
 
2.1.2 Repertoire of immune-dominant gluten epitopes activating a 
CD4
+ 
T cell response in adult subjects with celiac disease 
Gluten, the trigger factor in celiac disease is a heterogeneous mix of 
hundreds of proteins that can be divided according to their 
electrophoresis mobility in gliadin (gliadins) and glutenin 
(low and high molecular weight). Gluten proteins are monomers or 
polymers, these latters linked by inter-chain disulphide bonds, and rich 
in glutamine and proline, but poor in charged amino acids (14). The 
wheat genome is high redundant, and consequently in a single wheat 
variety several hundred different gluten proteins are found. The majority 
of gluten peptides are involved in the pathogenesis of CD (10). Different 
research groups, for many years, made a great effort to identify the 
repertoire of gluten epitopes that play a relevant role in the immune-
pathogenesis of celiac disease (9-11, 15-20). These understanding has 
been possible by the use of long-term T cell lines, and T cell clones 
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derived from intestinal biopsies of celiac patients; since it has been found 
that gluten specific CD4
+ 
intestinal T cells can be isolated from intestinal 
biopsies of celiac patients (9,11,15). These studies have provided the 
identification of several immunogenic peptides, derived from wheat and 
from the other prolamines, able to activate specific intestinal CD4
+
T 
cells in adult CD patients. 
Despite all these results, the great heterogeneity of gluten proteins (14), 
and technical limitations, in particular the limited number of cells that 
can be obtained from intestinal biopsies, together with the low frequency 
of antigen specific cells grown in vitro, make very complicated the 
identification of all gluten immunogenic peptides involved in celiac 
disease.  
To date several immunogenic  epitopes from -, -gliadin and glutenin 
have been identified to activate intestinal CD4
+
T-limphocytes (8, 9, 16-
18) in celiacs. 
One of these, a single 33-mer peptide mapping N-terminal 57-89 region 
of -gliadin was shown to have the highest T-cell stimulatory capacity in 
a large cohort of CD patients (LQLQPFPQPQLPYPQPQLPYPQ 
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PQLPYPQPQPF) (18). This peptide is highly resistant to proteolitic 
gastrointestinal digestion, and contains six copies of 3 different epitopes 
DQ2.5-glia-a (PFPQPELPY), DQ2.5-glia-b (PYPQPELPY), 
DQ2.5-glia-(PQPELPYPQ) (10). Recently it has been demonstrated 
that 17-mer peptide (QLQPFPQPQLPYPQPQP), corresponding to 
truncated form of 33-mer, shows immune-stimulatory similar to the 
longer peptide. Similarly, it has been identified another 17-mer derived 
from ω-gliadin DQ2-ω-1, that containing the DQ2.5-glia-1 and DQ2.5-
glia-2 epitopes frequently recognised by CD4+T lymphocyte from 
DQ2
+
celiacs from different countries (9, 19). 
A large and heterogeneous pattern of immunogenic peptides has been 
found in the γ-gliadins, although DQ2.5-glia-γ1 shows high reactivity 
properties in DQ2
+
 patients (Table 2.1.1) (9, 20).  
86 
 
 
Epitope Previous name Peptide-binding register, P1-P9     
                    1  2  3  4  5  6  7  8  9      
DQ2.5 restricted epitopes 
  
DQ2.5-glia-1a  DQ2--I, 9  P  F  P  Q  P  E  L  P  Y            
DQ2.5-glia-1b  DQ2--III    P  Y  P  Q  P  E  L  P  Y            
DQ2.5-glia-2  DQ2--II, 2  P  Q  P  E  L  P  Y  P  Q            
DQ2.5-glia-3  glia-20     F  R  P  E  Q  P  Y  P  Q             
     
DQ2.5-glia-1  DQ2--I      P  Q  Q  S  F  P  E  Q  Q             
DQ2.5-glia-2  DQ2--II     I  Q  P  E  Q  P  A  Q  L            
DQ2.5-glia-3  DQ2--III    Q   Q  P  E  Q  P  Y  P  Q            
DQ2.5-glia-4a  DQ2--IV     S  Q  P  E  Q  E  F  P  Q            
DQ2.5-glia-4b  DQ2--VIIc    P  Q  P  E  Q  E  F  P  Q            
DQ2.5-glia-4c  DQ2--VIIa   Q  Q  P  E  Q  P  F  P  Q            
DQ2.5-glia-4d  DQ2--VIIb   P  Q  P  E  Q  P  F  C   Q       
DQ2.5-glia-5  DQ2--VI     Q  Q  P  F  P  E  Q  P  Q              
 
DQ2.5-glia-1  DQ2--I     P  F  P  Q  P  E  Q  P  F            
DQ2.5-glia-2  DQ2--II    P  Q  P  E  Q  P  F  P  W            
  
DQ2.5-glut-1   glutenin-17  P  F  S  E  Q  E  Q  P  V              
DQ2.5-glut-2   glutenin-156  F  S  Q  Q  Q  E   S  P  F            
      
DQ2.5-hor-1   Hor-9, H9  P  F  P  Q  P  E  Q  P  F             
DQ2.5-hor-2   Hor-2, H2  P  Q  P  E  Q  P  F  P  Q             
DQ2.5-hor-3   hor-I       P  I  P  E  Q  P  Q  P  Y            
 
DQ2.5-sec-1   Sec-9, S9  P  F  P  Q  P  E  Q  P  F             
DQ2.5-sec-2   Sec-2, S2   P  Q  P  E  Q  P  F  P  Q             
DQ2.5-sec-3   DQ2-Sec-I    ? 
 
DQ2.5-ave-1a   Av-9A      P  Y  P  E  Q  E  E  P  F             
DQ2.5-ave-1b   Av-9B, 1490  P  Y  P  E  Q  E  Q  P  F             
 
 Table 2.3.1: List of celiac disease T cell epitopes recognized by CD4
+
T cells 
[Sollid et al,. Immunogenics 2012 (20)]. 
 
Recently, a great boost in this direction was given by a new in vivo 
approach used by Anderson and co-workers, to identify gluten specific T 
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cells, able to overcame all these problems related to the use of intestinal 
T cells (21). 
This procedure requires the administration to celiac patients on GFD of 
wheat bread for few days (3 days). Following oral challenge, specific T 
cells, can be found in peripheral blood of patients, using the sensitive 
IFN-EliSpot assay. This innovative methodology, found reproducible 
in different cohorts of celiacs (22-24), opens to new tools for 
investigation of immune pathways activated by gluten, as well as in the 
clinical practice. By this approach, recently J.A. Tye-Din and co-workers 
have screened a large library of 20-mer epitopes derived from different 
gliadin and prolamines as hordein and secalin (19), giving a great 
contribution to the identification of immunogenic gluten epitopes. A 
high degree of T cells redundancy was observed among celiacs (21), 
however three peptides were found responsible of the great majority of T 
cell responses (DQ2.5-glia-1a, DQ2.5-glia-2; DQ2.5-glia--1, 
DQ2.5-glia--2; DQ2.5-glia-γ-1). 
Collectively, these studies have formed the basis for novel a diagnostics 
and therapies, some of them are currently under clinical investigation. 
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The comprehension of the T cell immune stimulatory gluten peptides, 
involved in celiac disease, lead to identification of new therapeutic 
strategies (25). In the current state, the only treatment for celiac disease 
is represented by gluten free diet. This dietary consists in the completely 
avoidance of wheat gluten from the diet. Such dietary treatment allows 
to ameliorate all lesions of intestinal mucosa, and to normalize 
serological markers of disease, however it does not guarantee a 
permanent recovery of disease. In fact, if celiac patients enter in contact 
with gluten, the intestinal immune cells can be reactivated, resulting in 
the intestinal mucosa damage.  
Furthermore gluten free diet has not a perfect compliance (26% of 
children and 82,5% of adult show signs of intestinal damage after 2 years 
of dietary treatment) (4) due to different reasons, particularly for 
difficulty in finding gluten-free food (26) In addition GFD may creates 
some issues in social activities related to food. In addition there is a 
minority of patients that suffers of refractory celiac cases, in which the 
diet is not efficacious, and require a pharmacological, anti-inflammatory 
treatment (27). 
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Celiacs on gluten free diet for many years, can present nutritional 
deficiency, and could present a significant risk to develop obesity or 
metabolic syndrome, also those strictly comply this diet (28, 29). These 
deficiencies could be related to nutritional properties of gluten free 
products and to the high glycemic index, and caloric density of cereal 
used, that often are poorer in nutrient levels than naturally wheat grain 
(28).  
For all these reasons identify a new therapeutic strategy to treat celiac 
disease will be important for a large part of celiac population. One 
strategy currently under investigation is peptide-based immunotherapy, 
already used to treat other auto-immune disease or allergies (30, 31). 
Peptide based immunotherapy aims to immune-reactivity modulation, by 
induction of tolerogenic response, and elimination of the inflammatory 
state (32). It has been demonstrated that subcutaneous or sublingual 
administration of immunogenic peptides, activates the tolerogenic 
immune pathways. The results of peptides based-immunotherapy are 
modulation of immune-reactivity, with down-regulation of the immune 
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response and stimulation of regulatory T cells. A clear application of this 
method is represented by the vaccines (30, 33). 
In order to design a potential immunotherapy for CD, the detailed 
comprehension of the T-cell stimulatory epitopes, and of their possible 
immune-dominance, is necessary.  
A current perspective of peptide-based therapeutic vaccine in celiac 
disease is represented by Nexvax2. This drug includes three epitopes that 
results immunodominant in HLA-DQ2 celiacs. Currently Nexvax2 is on 
Phase II clinical trial in adult celiac patients in both Australia and USA, 
in order to assess its efficacy in controlling of inflammatory state (34). 
However, the feasibility of such applications will depend upon 
consistency of the immune response to gluten peptides despite the gluten 
cereal consumed, duration of disease and age. 
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2.2 AIM 
Since the immune response to gluten in children with CD is poorly 
studied, this project aims to provide an understanding of the T cell 
immune-stimulatory gluten peptides involved in childhood celiac 
disease. Furthermore, we have also investigate the role of the 
deamidation by tTG on the stimulatory properties of gluten peptides in 
children with classical and potential celiac disease by looking at 
intestinal CD4
+
T cell response to both native and deamidated gluten.  
This project comprises the following experimental phases: 
 Analysis of immune reactivity to known immunodominant gliadin 
epitopes in children with overt celiac disease. 
 Analysis of adaptive, CD4+Tcell-mediated responses in the 
intestinal mucosa of children with potential celiac disease 
 Identification of immunogenic gliadin peptides in potential celiac 
disease 
 Investigation of the role of the deamidation by tTG on the immune 
recognition of gluten in the intestine of very young subjects with 
CD. 
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2.3 MATERIALS AND METHODS 
2.3.1 Selection and synthesis of gluten peptide library and control 
antigens 
Peptic-tryptic digestion of gliadin (PT-gliadin) has been obtained 
following extraction from Strampelli grains as elsewhere destribed (14), 
and enzymatically digestion with pepsin and trypsin (35). Gliadin 
peptides (Table 2.3.1) were synthesized by solid-phase automated flow, 
as previously described (9).  Both gliadin and peptides were deamidated 
with guinea pig tTG (Sigma- Aldrich, St. Louis, MO, USA), as reported 
elsewhere (9). 
This phase of project was performed in collaboration with researchers of 
Institute of Food science-CNR, Avellino.  
 
Table2.3.1: Gliadin peptides analyzed in this study 
 
93 
 
2.3.2 Recruitment of population study 
Children were enrolled at “Section of Pediatrics”, at the Department of 
Translational Medical Science, University of Naples “Federico II”. 
Children were enrolled based on suspected CD or potential celiac disease 
on the basis of positive CD serology (anti-endomysial antibodies (EMA) 
and/or of anti-tissue transglutaminase (anti-tTG) antibodies). All 
children who received CD diagnosis were retained in the study, and with 
the parents‟ informed signed consent to the experiments. 
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Table 2.3.2: List of Children enrolled in this study 
 
2.3.3 Isolation of PBMC from peripheral blood 
Peripheral blood mononuclear cells (PBMC) were isolated from 
heparinised whole blood using Ficoll (Ficoll-PaqueTM PLUS-GE 
Healthcare, UK) gradient separation. 
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2.3.4 Generation of gliadin-specific, polyclonal T cell lines 
All children enrolled underwent to Jejunal biopsies. This biopsies of 
about 3-4 mm in size, were enzymatically digested with collagenase-A 
(1mg/ml, Roche, Basel, CH), for 1hour at 37°C and 5% CO2. Isolated 
cells were stimulated with irradiated autologous PBMCs, and 
deamidated gliadin (25µg/ml) or both deamidated and naive gliadins 
(25µg/ml) used as antigen. 
48-hours later stimulation, were added 1ml of fresh medium, and IL-15 
(10ng/ml) and IL2 (40U/ml) (R&D System, Minneapolis, MN). At day 
7, T-cell lines (TCLs) generated were re-stimulated once more with 
autologous PBMCs and PT-gliadin±tTG; IL-15 and IL2 were added after 
48-hours and every subsequent 3-4 days. Long term TCLs were 
generated by cycling of restimulation with Phytohaemagglutinin (Roche, 
Basel, CH) and heterologous PBMCs.  
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2.3.5 T cell Assay 
T cell lines generated from intestinal biopsies were assayed in response 
to gliadin and gliadin peptides. T cells were seeded in a 96-well plate, 
autologous or HLA matched EBV were used as APC (antigen presenting 
cells), gliadin (50g/ml) or gliadin peptides (30g/ml) were used as 
antigens. Cells were incubated at 37°C and 5% CO2. 48-hours later, 
supernatant, derived from T cell assay, were collected and used to 
assayed IFN- levels using Elisa Assay. 
 
2.3.6 IFN ELISA assay 
A 96-well high binding (Corning, NY) plates were coated with anti-
human (1g/ml) IFN-mAb (Mabtech, OH) overnight at 4°C. 
Thereafter, plates were washed (PBS-Tween 20-Sigma-Aldrich, St. 
Louis, MO), and blocked with blocking solution (PBS+2%BSA-Sigma-
Aldrich, St. Louis, MO) for 2-hours at room temperature. Cell 
supernatants, previously collected by T-cell assay, were added to plate 
overnight at 4°C.  
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Thereafter, plate were washed, and incubated with biotinylated anti-IFN-
(Mabtech, OH) at 1 g/ml, 1-hour at room temperature, and subsequent 
incubated with Streptoavidina HRP (BD-Pharmingen, Franklin Lakes, 
NJ) in a diluition buffer. The addition of 3,3',5,5'-tetrametilbenzidin 
(TMB, Sigma-Aldrich, St. Louis, MO) diluted in a Substrate buffer 
(citric acid monohydrate pH4.2) allow to quantified IFN levels produced 
using spectrophotometer.  
 
2.3.7 IFN-EliSpot assay 
Peptides specific T cells responses were observed using-IFN EliSpot 
Assay. T cells (3x10
4
) were seeded on a 96 wells nitrocellulose backed 
plate (MAHA S4510- Millipore, Bedford, MA), previously coated with 
anti (10g/ml) IFN-mAb (Mabtech, OH) over-night at 4°C. Autologous 
or HLA matched EBV were used as APC (antigen presenting cells), and 
gliadin (50g/ml) or gliadin peptides (30g/ml) were used as antigens. 
Cells were incubated 48-hours at 37°C and 5% CO2. 
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Following cells incubation, plates were treated with biotinylated anti-
IFN-Mabtech, OH) 2-hours at room temperature. Thereafter plates 
were washed with PBS-0,05% Tween20 (Sigma-Aldrich, St. Louis, MO) 
and then incubated with Streptoavidina HRP (BD-Pharmingen, NJ) in a 
dilution buffer (PBS1X/BSA1%, Sigma- Aldrich) for 1h at room 
temperature. The addition of aminoethylcarbazole (AEC, Sigma- 
Aldrich) solution for five minutes, make detected cytokines releasing 
cells by using ELISPOT image analysed (A.EL.VIS.) 
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2.4 RESULTS 
2.4.1 Recognition of known immunodominant gliadin peptides in 
children with classical form of celiac disease 
As above mentioned, the identification of gluten epitopes plays an 
important role in the characterization of celiac disease. Up to now a large 
panel of gliadin epitopes has been found immunogenic for adult CD 
patients. In order to characterize the involvement of the main of these 
peptides (listed in Table 2.4.1) in children form of disease, jejunal 
biopsies were collected, and T cell lines generated from children with 
overt celiac disease.  
 
Table2.4.1: Panel of gliadin peptides assayed in children celiac  
 
Specific reactivity to deamidated-peptides generated by T cell lines was 
measured using IFN- ELISA/EliSpot assays. Peptic-tryptic digest of 
gliadin has been used as control.  
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a)  
b)  
c)  
Figure 2.4.1: Specific responses to Pt-gliadin and gliadin peptides in celiac children CD3 a), CD6 b) 
CD7 c)  
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In figure 2.4.1 we have shown representative results obtained in three 
celiac children. Patient CD3 (part a) has shown very high production of 
IFN-in response to P3 (DQ2.5-glia-γ1) peptide, and low production in 
response to P1 and P2 (DQ2.5-glia-1a/glia-2; DQ2.5-glia--1/glia--
2). Similar pattern of reactivity has been foun in patient CD6. 
In contrast, patient 7 have reported very high levels of IFN- secreting 
cells in response to P1 (DQ2.5-glia-1a/glia-2) peptide, and only weak 
levels in presence of P2 and P3 peptides (DQ2.5-glia--1/-glia--2; 
DQ2.5-glia-γ1). 
All T cell lines have shown reactivity to PT-gliadin. 
Collectively our data have indicated that T cell lines generated from 
children celiac recognized same gliadin peptides specifically identified 
in adult celiac patients. Furthermore, a great heterogeneity in reactivity 
to these peptides was found; with no prevalence response generated by 
one or more peptide(s). Similar pattern of responsiveness was previously 
found in adult affected by celiac disease (9). 
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2.4.2 T-cell mediated immune response to gliadin in potential 
In order to further improve comprehension of early phases of celiac 
disease, we decided to identify immune-responses to PT-gliadin in 
children celiac patients. We have decided to investigate gliadin reactivity 
found in T cell lines established following children intestinal biopsies; 
and in particular we have focused on immune responses obtained in 
potential celiac patients.  
We enrolled a population study composed by potential, celiac children, 
and non celiac controls. Using EliSpot Assay we measured IFN- 
secretion cells activated by deamidated PT-gliadin. Results were 
expressed as Net--IFN-SFC/106cells. Furthermore T cell lines were 
assayed with and without presence of antibodies neutralizing, in order to 
investigate the involvement of regulatory pathways in controlling the 
GALT responses to dietary gluten (37). We consider positive response 
that presented IFN- levels in presence of gliadin at least 2 value of 
medium alone. 
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In figure 2.4.2 we showed results obtained. In part A) we have 
represented responses from six children with acute disease (positive TTG 
and with villous atrophy). Results obtained were heterogeneous. A part 
of children celiac subjects have shown a positive production of IFN- in 
response to gliadin in at least one experimental condition (with or 
without neutralizing antibodies).We have found patients showing a 
significant response both with and without neutralizing Ab, or only with 
neutralizing Ab. Particularly patient 6 presents a positive response both 
with and without neutralizing antibodies. Similarly patient 1 and 5 
present significant responses only when were present neutralizing 
antibodies, and present borderline values in absence of these. Other two 
patients have shown border line values (1.8-1.9 values of medium alone) 
when we added neutralizing antibodies. 
Overall these results highlighted a heterogeneous pattern of reactivity to 
gliadin, but generally there is an increase in IFN- production in 
presence of neutralizing antibodies. 
In part B) we have shown results obtained thought IFN-EliSpot Assay 
in 9 children with positive TTG and with normal mucosa. We considered 
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these subjects as potential celiac. We assessed these T cell lines both in 
presence or absence of neutralizing antibodies. In our results we have 
found that 2 potentials (pot 2, 4,) presented a significant response to 
gliadin both with and without neutralizing antibodies, while patients 7 
and 9 only in presence of neutralizing antibodies. In addition we have 
found two subjects presenting borderline values (1.8-1.9 values of 
medium alone) when were added neutralizing antibodies, while one of 
subjects both whit and without neutralizing antibodies.  
A) 
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B) 
Figure.2.4.2 Gliadin specific T cell responses in children celiac (A), and potential celiac (B) with or 
without neutralizing antibodies 
 
Overall these data have demonstrated that along with T cell responses 
found in celiac children, we identified a clear reactivity to deamidated 
gliadin generated by T cell lines of potential celiac. Furthermore we have 
shown that both in acute and potential children celiac, the adaptive 
response to gliadin in children CD could be under control of regulatory 
pathways. 
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2.4.3 Comparative analysis of gliadin-specific T-cell responses 
In order to investigate the immune-responses generated, and gliadin 
specific reactivity found in potential celiac, we compared the responses 
found in these children to responses obtained in non celiac controls, and 
in children celiac patients. In figure 2.4.3 are shown results obtained by 
using ElisSpot IFN-assays in response to deamidated form of gliadin. 
Results were expressed as Net IFN- SFC/106 cells (SFC in the presence 
of Gliadin-TG minus SFC in absences of Gliadin).  
 
Figure2.4.3: Comparative analysis of T cell lines derived from HCs, Potential, Children and Adult 
celiacs 
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Our results have shown that no significant differences in IFN- 
production in response to PT-gliadin has been found, among potential-
CD, and both adult (p=0,69) and children celiac patients (p=0,86). In 
contrast, a great difference [(T-Test student (p<0,03)] have been found, 
when responses found in potential-CD were compared with responses of 
non celiac subjects.  
 
2.4.4 Recognition of adult immunodominant gliadin peptides by 
children with potential celiac disease 
We have already assessed the presence of gliadin specific T cells in 
potential celiac. In order to expand the investigation on potential celiac 
disease, we decided to assayed reactivity generated by main 
immunodominant gliadin epitopes, previously assessed in children celiac 
(Table 2.4.1) subjects. 
Results were obtained using Elisa Assays, and were shown as IFN- 
ng/ml. We considered responsive all these T cell lines that show IFN- 
levels in response to peptides at least 2 value of medium alone. 
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A) 
B) 
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C) 
D) 
Figure 2.4.4: Specific T cell responses from potential celiac patients to selected gliadin 
peptides 
 
In figure 2.4.4 is shown the representative immnune-responses to gliain 
peptides generated by T cell lines of potential children. Patient potential 
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4 presented very high INF- levels production in presence of P1 and P2 
(DQ2.5-glia-1a/glia-2; DQ2.5-glia--1/glia--2), no positive 
response has been found in response to P3 (DQ2.5-glia-γ1).  
In contrast, patient potential 7 has demonstrated a increased IFN- 
secretion in presence of all assessed epitopes, however only in presence 
of P3 (DQ2.5-glia-γ1), the response was clearly high. Similary, to 
potential 7, also potential 3 presented increase in IFN- production in 
presence of all selected peptides. However we have identified a very 
high response only when is present P2 peptide (DQ2.5-glia--1/glia--
2). 
Finally in patient Potential 1we found a very high IFN- production in 
response to P2 (DQ2.5-glia--1/glia--2). 
Overall these results have shown that potential celiac have T cells able to 
recognized main immune-dominat gliadin peptides with a high 
heterogenteity. All peptides have shown immunoreactive properties, and 
we have not found a dominant response by one or more peptides(s). 
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2.4.5 T-cell mediated immune response to gliadin in potential children 
Recently, one hypothesis occurs, suggesting that in first stages of 
disease, the T cells activation could be start in response to naive gliadin 
peptides. The consequent activation of inflammatory state could induce 
the activation of TG2 enzyme and follow deamidation of gliadin 
peptides. This state results in a further induction of T cells that could be 
driven toward immunodominant deamidated sequences of gliadin. 
To investigate the primary immune responses involved in first stages of 
celiac disease, and role of TG deamidation, we assayed gliadin reactivity 
of T cell lines derived from celiac and potential children. Particularly we 
measured IFN- by EliSpot/Elisa assays in response to gliadin, both in 
naive and deamidated form. The experiments were performed in 
presence of antibodies neutralizing the effect of IL-10 and TGF-β 
(10g/ml) added 10 minutes before antigens, in order to investigate the 
involvement of regulatory pathways (37). 
A total of fourteen TCLs were generated and assayed. We consider 
responsive all these T cell lines that showed IFN- levels in response to 
gliadin at least 2 the value of medium alone. 
112 
 
In figure 2.4.5 were shown results obtained in potential celiac. These 
results were expressed as fold increase (IFN- produced in absence of 
antigen/IFN- produced in presence of antigen). 
 
Figure 2.4.5: Responses to Gliadin Naive and Deamidated in potential celiac. Red Bars shown mean 
values found. 
 
Results (fig. 2.4.5) have shown a heterogeneous pattern of response, in 
particular in three children the responses to naive PT-gliadin exceeded 
cut-off value, but only in one of these the positivity was confirmed in 
presence of neutralizing antibodies. Furthermore three patients expressed 
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a positive T cell response in presence of deamidated gliadin, and two in 
presence of neutralizing antibodies in three of them.  
Also we have investigated the immune reactivity to gliadin by TCLs 
generated from six young classical celiac. We considered as classical 
celiacs children that after endoscopy show intestinal mucosa damage 
(T3). 
As shown in figure 2.4.6 in four children the immuno responses resulted 
positive at least in one experimental condition. Three children responded 
to gliadin with and without neutralizing antibodies, three were 
responsive in presence of deamidated gliadin, while four in response to 
deamidated gliadin with neutralizing antibodies. 
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Figure2.4.6: Specific T cell responses to gliadin Naïve and Deamidated in celiac children. Red bars 
shown mean value. 
 
The trend of the responses that we have identified shown a growing 
increase in the IFN- production in response to both naive and 
deamidated PT-gliadin. This positivity has been found accentuated, in 
progressive manner, in presences of neutralizing antibodies. The amount 
of increase was generally higher in response to pt-naive than deamidated 
gliadin.  
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Overall these data indicated that both potential and celiac children have 
present T cells reactive both to naive and deamidated gliadin. Generally 
the presence of neutralizing antibody caused an increase in IFN-
production, highlighting that regulatory pathway could play a role in 
the regulation of adaptive T cell response. 
 
2.4.6 T-cell mediated immune response to gliadin peptides 
Previously we have investigated reactivity of T cells derived from celiac 
children to TG-epitopes. To extend our knowledge about role of 
deamidation in the onset of disease, and on role of gliadin peptides we 
evaluated reactivity to five epitopes identified previously 
immunodominant in adult affected by celiac disease.  
 
Table 2.4.2: Complete list of gliadin peptides assayed 
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In addition we assessed these peptides both in naive and deamidated 
form. In all experiments Pt-gliadin has been used as control. 
In the following figures were have shown the responses to selected 
peptides. Results have been presented as IFN- ng/ml. We considered 
positive responses that exceeding 2 value of medium alone.  
CD#11 presented a very high response to P4 both in naive and 
deamidated form. Lower positive response was found towards P2, P3, 
P5, and to naive form of P1.  
 
Figure 2.4.7: Responses obtained in patient CD11 in response to gliadin peptides in naïve and 
deamidated form  
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CD#12 has shown a positive response to P1 (DQ2.5-glia-1a/glia-2) 
and to P4 in naive and deamidated, while no significant responses have 
been found in response to other peptides. 
 
Figura 2.4.8: Responses obtained in patient CD12 in response to gliadin peptides in naïve and 
deamidated form 
 
Patients CD#9, has shown immune reactivity especially in response to 
deamidated form of gliadin peptides. In particular significant levels of 
IFN- were identified in response to deamidated P2 and P5 peptides.  
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Figure 2.4.9: Responses obtained in patient CD9 in response to gliadin peptides in naïve and 
deamidated form 
 
Furthermore we have shown results obtained in patient CD#13, we 
identified a clear increase of IFN- production in response to P1(DQ2.5-
glia-1a/glia-2) and P2 in naive form, we do not confirm these 
responses in deamidated form. In contrast we identified an immune 
response to deamidated P4 and P5 peptides.  
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Figure 2.4.10: Responses obtained in patient CD13 in response to gliadin peptides in naïve and 
deamidated form 
 
In the following figure we have displayed the profile of responses to 
different peptides, in our patients. Overall we found that all patients 
produced IFN- in response to almost one naive and deamidated 
peptides.  
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Table 2.4.4: Profile of peptide recognition in children patients 
 
A total of two patients have been found responsive to naive form of P1, 
rising up to three with deamidated form. Furthermore we have found that 
three patients produce specifically IFN-in response to naive form, two 
in presence of deamidated form. Only one child has responded both, to 
naive and deamidated form of P3. Also, we have identified two patients‟ 
responders to naive P4, four to deamidated form. Finally we can see that 
two patient responded to P5 naive confirming responses to P5-
deamidated. 
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Figure 2.4.11: Responses obtained in potential 14 in response to gliadin peptides in naïve and 
deamidated form 
 
Finally to have first indication on the involvement of these peptides in 
potential deamidation we showed results obtained in potential #14. In 
this child in addition to a significant response to pt-gliadin, we found a 
clear reactivity to P5 in deamidated form. 
Overall these data have demonstrated that children CD patients, and by 
first indication also potential patients recognized immunodominant 
peptides. The responses were heterogeneous, since no immune-
prevalence of one or more peptides has been found. Furthermore naive 
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form of peptides have been similarly recognized, and with a similar 
magnitude in IFN- secretion.  
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2.5 DISCUSSION 
Calic Disease is a gluten (or releated prolamines) mediated enteropathy, 
that affects genetically susceptible individuals carrying HLA class II 
DQ2 or DQ8 (38). 
It has been widley demonstrated that CD presents a wide spectrum of 
clinical manifestation, that often makes difficult the identification of all 
affected patients. Among different forms of celiac disease it‟s possible to 
identify children with histologially normal mucosa, and positive 
antibodies. Ferguson have defined these patients potential celiacs (39).  
Over the years, the number of publications about celiac disease has 
increased enormously to elucidate all clinical and immunological 
characteristics of CD. Despite that, currently, the only effective 
treatment for CD is gluten free diet. The use of these treatment is widley 
accepted for classic celiacs, however and its use is under debate in 
potential celiac (13, 40-43). 
Further studies aimed to elucidate the repertoire of pathogenic gluten 
epitopes immune-dominant in celiac disease, and the network of 
cytokines produced following the activation of T-cells. These 
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information provide important tools for diagnosis of disease, and for 
engineering of alternative therapy such as peptide-based immunotherapy 
(31, 32) 
Recently Camarca and co-workers have assessed the specific immune-
reactivity of twenty-one peptides, derived from gliadins and glutenis, by 
using polyclonal T cell lines from DQ2
+
 celiac adult subjects. Results 
show a high heterogeneity of responses to these epitopes, and revealed 
the possible involvement of - and - gliadins for CD pathogenesis (9).  
In our project we extended these analysis to children with classical celiac 
and potential celiac disease. Since a complete study of large gluten 
peptides library in pediatric CD is feasible, for the reduced amount of 
blood draw, we assessed in first instance three peptides derived from -, 
-, and -gliadin, found immune-dominant in adults with celiac disease, 
and investigated the contribution to the gluten-specific T cell response, 
in childhood CD. Surprisingly, our results show that intestinal T cell 
lines from celiac children were specifically activated by same set of 
gliadin immune-dominant epitopes recognized by adults celiac. No 
prevalence of one peptide-specific response was found, and furthermore 
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our patients gave a heterogeneous array of responses. Similar results 
have been found also in adults (9). 
As expected our data confirmed presence of reactive T cells in villous 
atrophy in celiac children (8). Remarkable, these results show a clear 
presence of gliadinTG specific T cells in a part of potential-CD. 
Unexpectedly we found a significant IFN- production also in patients 
whose tTG antibody-titer were fluctuating, and it seems that does not 
depend on Marsh grade (two T1 and one T0). The low frequence of 
reactive T cells derived from children found in this study, may be 
because difficult to in vitro expanding and maintaining gliadin specific T 
cells following polyclonal stimulation with PHA. Previously studies 
reported that a part (35,3%) of potential celiac develops villous atrophy 
over time (3 years) (13), also sign of T-cell activation, with increased + 
cells have been identified (12, 43).  
Recently it has been highlighted that a large proportion of potential 
celiac patients, despite persistent positive anti-TG2, don‟t develop 
intestinal damage after 9 years of follow-up. The Authors have identified 
3 Single Nucleotide Polymorphisms (SNP) of genes (previously 
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associated to celiac disease) that contribute to predict cases who develop 
intestinal lesion. All these genes were involved in the pathogenesis of the 
gluten-induced damage (Auricchio R. et al. in press American Journal of 
Gastroenterology.2014). The expression of one of these genes IL2-IL21 
gene has been previously studied in potential celiac disease. In particular 
it has been found suppressed in potential phenotype (44). Overall these 
data highlighted that regulation of these gene is associated to 
pathogenesis of CD. 
Furthermore by ex-vivo study Westerholm-Ormio and coworkers, 
reported that density of IFN- cells in epithelium of potential celiac 
patients was found higher than the density of controls, and was found 
higher in overt CD than potential patients. Our findings had shown no 
statistically difference in magnitude of IFN- production among potential 
and celiac (45) patients. Overall our data results are important to our 
knowledge, because they described the presence of this cytokine in 
potential celiac patients. This is important to investigate the possible start 
up of inflammatory process which is required to develop overt CD.  
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Furthermore, in our study all pattern of responses investigated, both in 
potential and overt celiacs were regulated and influenced by regulatory 
pathway. All responses were modulated in presence of antibodies 
neutralizing IL10R and TGF, two citokynes involved in controlling of 
Treg cells. Several studies have suggested that the immunosuppressive 
cytokines such as IL-10 and TGF-have an important role in maintaining 
intestinal tolerance both in mouse and human (37, 46-49). Our data were 
consisitent with previously published data that suggest presence of Treg1 
in intestinal mucosa of celiac patients (37), and confirmed role of 
regulatory system in celiac and in potential celiac disease. Tr1 cells 
down-regulate naive and memory T cell responses upon local secretion 
of IL-10 and TGF-(). In concordance with this hypothesis we identified 
an increase in IFN- production in presence of mentioned cytokines. 
To confirm presence of immune-reactivity in potential CD patients, 
recent evidences have identified signs of immunological activation in 
small intestinal mucosa of potential celiac (50). The Authors found that 
IFN-γ-RNA expression is correlated to intestinal lesions, since it was 
found lower in potential children than in overt celiac. They hypothesized 
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that regulatory mechanisms prevent the progression toward a complete 
mucosal damage. Furthermore they found levels of IL-10 RNA 
expression higher in potential with Marsh 0 than potential with Marsh 1 
lesions, confirming the involvement of IL-10 in controlling of 
inflammatory responses (50).  
In potential CD low grade of inflammation may be related to protective 
regulatory system that prevents progression toward intestinal damage. In 
agreement with studies suggesting presence of Treg cells in CD, in our 
study we identified a heterogeneous panel of responses to gliadin and 
gliadin peptides, but generally the IFN--production seems to be 
increased by neutralizing protective effect of Treg. 
Interestingly we found by comparative analysis of IFN- secretion 
between potential, celiac (adult and children) patients, and non celiac 
controls that a significantly different responses among potential and non 
celiac controls (this data is confirmed when compared celiac and non 
celiac) was found. This data could provide a clinical support in cases 
which diagnosis is difficult.  
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Remarkable, our results reported that T cell lines reactive to three 
immuno epitopes of -- and -gliadin were found in celiac childen, 
despite a large heterogenety in set of responses. Furtermore, we have 
shown that potential have similary pattern of responses to celiacs, with 
absence of a predominant immunodominance from one or plus peptides. 
Previously Vader and coworkers identified a panel of novel epitopes 
recognized from celiac children DQ2
+
. For these patients a large 
heterogeneity in the specificity of T cells was observed. No strong 
immunodominance was found, since the responses were directed to 
different set of peptides (8). 
Overall these data highlighted a great hetereogenus immunogenicity and 
suggest that probably several epitopes were involved in onset and 
development of celiac disease. 
In the last part of this study, we focussed our attention on role of 
deamidation in celiac disease. In our population immune-reactivity to 
naïve and deamidated gliadin, in both potential and overt celiac, was 
found. Overall we identified a positive reactivity to deamidated gliadin 
in (~70%) celiac and (~50%) and potential. Surprisingly similar 
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reactivity to gliadin in naïve form were identified in celiac (50%), while 
lower responses (~38%) were found in potential celiac. In potential CD 
role of neutralizing antibodies seems to be less relevant. However may 
not be true, because due to technical issues not all responders to naïve 
gliadin were assayed in presence of neutralizing antibodies. Generally 
we confirmed that potential and celiac children have shown a response to 
naïve and deamidated gliadin with increasing responses in presence of 
neutralizing antibodies.  
According to several studies, T cell lines and clones isolated from adult 
celiacs patients were specifically activated by deamidated gluten 
peptides (15). Specific reactivity to naïve variants were not or only 
faintly found. First in 2002 Vader and co-workers have analyzed naïve 
and deamidated gluten cells reactivity in T cell lines generated from 
pediatric celiacs. Results highlighted a great heterogeneity in intestinal T 
cell responses, with a number of patients responsive to deamidated 
and/or to naive form of gliadin. Furthermore specific response to some 
identified peptides did not required deamidation to be active. Basing on 
these features, the Authors hypothesized that in celiac patients T cell 
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response could start toward non deamidated gliadin peptides, and 
subsequently be driven toward deamidated epitopes. Recognition of few 
native peptides could trigger the IFN- production responsible of a 
positive inflammatory loop and of consequent low-grade inflammation 
that lead to tissue damage and to TG2 release (8). The result is that the 
CD4
+
T cell response is strongly enhanced with more IFN- production, 
with tissue damage, and increased release of TG2. Alternatively 
infections may occur in the gastrointestinal tract and activate the loss of 
tolerance to naive gluten peptides and activation of TG2. 
In accordance with this hypothesis our data show reactivity to gliadin 
and to five immune-dominant gliadin peptides assayed. We identified a 
large heterogeneous set of responses. Surprising one patient (CD13) 
failed to recognize gliadin, but showed reactivity to naive DQ2.5-glia-
1a, -2 and DQ2.5-glia--1,--2, and to DQ2.5-glia-γ-1 -gliadin 
epitopes.  
Overall these data could be useful to define the repertoire of gluten 
peptides relevant for CD pathogenesis and their immune reactivity. The 
identification of bioactive gluten peptides, involved in CD, could be used 
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for the engineering of a peptide-based therapy (31). To date a large 
number of gluten peptides are identified for their ability to stimulate T-
cell responses. Several studies on Norwegian and Scandinavian subjects 
converged in finding a genic region encompassing 33-mer peptide of -
gliadin highly T-cell stimulatory capacity (15,18). Contrasting results 
were obtained from a Netherland group showed that only 50% of 
intestinal T-cell lines from adult CD patients were reactive to epitopes of 
N-terminal region of alpha-gliadin (8). Two immunodominant peptides 
corresponded to the α-glia-17mer and the DQ2-ω-1 found highly 
reactive in Italian CD cohort. Recently a large screening (9), have 
allowed the identification of several epitopes derived from gliadin and 
related prolamines (19). Collectively, these studies have formed the basis 
for novel diagnostics and therapies, some of which are currently under 
clinical investigation.  
To data it is indeterminate the number of gluten immunogenic peptides. 
Despite the large number of immunogenic peptides identified until now, 
the reduced diversity in T cell responders, and the high redundancy in 
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gluten peptides recognised open the doors to new peptide based 
immunotherapy. 
Up to now it has been shown that the repertoire of antigens involved in 
the beginning of the immune response to gluten, and in active CD and in 
potential CD, could be different from those found in adults CD subjects. 
Our results confirmed that children may present a high specificity to 
gluten peptides found immunodominant in adult celiac patients.  
In conclusion, our data provided that in potential CD there are evidences 
of inflammatory pathway, despite the absence of intestinal damage.  
To improve our knowledge, potential celiac disease represents an 
important system to understand the pathways that are able to induce the 
intestinal damage in genetically predisposed individuals, and clarified 
the events necessary to onset of the disease.  
Could be interesting further to explore factors involved in first stages, 
and then in progression of mucosal damage. 
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